--- title: "002728.SZ (002728.SZ) — Related News" type: "Symbol" locale: "en" url: "https://longbridge.com/en/quote/002728.SZ/news.md" symbol: "002728.SZ" name: "002728.SZ" parent: "https://longbridge.com/en/quote/002728.SZ.md" datetime: "2026-05-20T05:51:36.922Z" locales: - [en](https://longbridge.com/en/quote/002728.SZ/news.md) - [zh-CN](https://longbridge.com/zh-CN/quote/002728.SZ/news.md) - [zh-HK](https://longbridge.com/zh-HK/quote/002728.SZ/news.md) --- # 002728.SZ (002728.SZ) — Related News ### [TY PHAR. released its first-quarter performance, with a net profit attributable to the parent company of 25.7632 million yuan, a year-on-year decrease of 18.39%](https://longbridge.com/en/news/284224560.md) *2026-04-27T13:17:35.000Z* > TY PHAR. released its Q1 2026 performance report, with operating revenue of 210 million yuan, a year-on-year decrease of ### [Under the game of centralized procurement and innovation, the transformation difficulties of established traditional Chinese medicine companies have intensified](https://longbridge.com/en/news/283680662.md) *2026-04-22T13:44:36.000Z* > In the game between centralized procurement and innovation, established traditional Chinese medicine companies are facin ### [TY PHAR. : Obtained the invention patent for "A Concentrated Extraction Device and Extraction Method for Traditional Chinese Medicine Materials Integrating Waste Residue Prevention."](https://longbridge.com/en/news/282958540.md) *2026-04-16T07:47:04.000Z* > TY PHAR. announced that the company recently obtained an invention patent certificate issued by the National Intellectua ### [TY PHAR. plans to grant 13.7296 million restricted shares](https://longbridge.com/en/news/281330965.md) *2026-04-01T08:42:11.000Z* > TY PHAR. disclosed the 2026 restricted stock incentive plan, intending to grant 13.7296 million restricted shares to 197 ### [TY PHAR. released its 2025 annual performance, with a net profit attributable to the parent company of 81.6716 million yuan, an increase of 298.5%](https://longbridge.com/en/news/280167735.md) *2026-03-23T13:06:46.000Z* > TY PHAR. released its 2025 annual report, with operating revenue of 925 million yuan, a year-on-year increase of 34.42%; ### [TY PHAR. : Net profit of 50.3319 million yuan in 2025, a year-on-year increase of 1.34%](https://longbridge.com/en/news/275729732.md) *2026-02-12T09:11:03.000Z* > TY PHAR. released its performance report, achieving an operating income of 288 million yuan for the fiscal year 2025, a ### [Lin Yuan takes action! Policies bring warmth! The A-share "drinking and medicine" market begins!](https://longbridge.com/en/news/275127717.md) *2026-02-06T12:39:59.000Z* > Recently, the liquor and traditional Chinese medicine sectors have rebounded under favorable policies and market capital ### [Traditional Chinese medicine concept stocks are active! With frequent policy tailwinds, is a rebound expected by 2026?](https://longbridge.com/en/news/275122974.md) *2026-02-06T11:59:33.000Z* > Chinese medicine concept stocks are performing actively in the A-share and Hong Kong stock markets, with multiple stocks